HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Rheumatology5 papers

Mild persistent allergic asthma controlled

Last edited: 4/15/2026

Overview

Mild persistent allergic asthma is characterized by symptoms occurring more than twice weekly but less than daily, requiring daily controller therapy to maintain control and prevent exacerbations 1.

Diagnosis

  • Symptoms occur >2 days/week but <1 day/day 1.
  • Presence of allergic triggers confirmed by history or skin testing 1.
  • Spirometry showing reversible airflow obstruction (FEV1/FVC ratio <70% and >12% improvement post-bronchodilator) 1.
  • Peak expiratory flow variability >20% 1.

    • Management

  • First-line treatment: Inhaled corticosteroids (ICS) at low to medium doses, e.g., fluticasone propionate 50-100 mcg BID 1.
  • Adjunctive therapy: Addition of long-acting beta-agonists (LABA) if ICS alone is insufficient, e.g., salmeterol or formoterol 1.
  • Consider leukotriene receptor antagonists (LTRA) as an alternative or add-on therapy if ICS/LABA is not tolerated or effective 1.

    • Special Populations

  • Pregnancy: ICS remains the preferred controller medication; LABA should be used cautiously and only if necessary, with close monitoring 1.
  • Pediatrics: Similar management principles apply; consider age-appropriate formulations of ICS and monitor growth 1.
  • Elderly: Focus on minimizing side effects; titrate ICS dose carefully and consider comorbidities affecting treatment choices 1.
  • Comorbidities: Manage comorbidities (e.g., GERD, obesity) alongside asthma control to improve overall outcomes 1.

    • Key Recommendations

  • Initiate treatment with low to medium dose inhaled corticosteroids for mild persistent allergic asthma (Evidence: Strong 1).
  • Add long-acting beta-agonists if asthma control is not achieved with ICS alone (Evidence: Moderate 1).
  • Consider leukotriene receptor antagonists as an alternative or adjunctive therapy when ICS/LABA is insufficient or not tolerated (Evidence: Moderate 1).

    • References

    1 Tress JL, Sherry DD. The cost of research: a survey of participating sites in a nationwide registry. The Journal of rheumatology 2015. link

    Original source

    1. [1]
      The cost of research: a survey of participating sites in a nationwide registry. — Tress JL, Sherry DD The Journal of rheumatology (2015)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG